Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review

被引:50
作者
Dandona, Paresh [1 ]
Dhindsa, Sandeep [1 ,2 ]
Ghanim, Husam [1 ]
Saad, Farid [3 ]
机构
[1] SUNY Buffalo, Div Endocrinol Diabet & Metab, Williamsville, NY 14221 USA
[2] St Louis Univ, Div Endocrinol Diabet & Metab, St Louis, MO 63103 USA
[3] Gulf Med Univ, Res Dept, Ajman, U Arab Emirates
关键词
body composition; diabetes complications; insulin resistance; type; 2; diabetes; weight control; HORMONE-BINDING GLOBULIN; ANDROGEN DEPRIVATION THERAPY; TYPE-2; DIABETES-MELLITUS; SKELETAL-MUSCLE; INSULIN-RESISTANCE; BODY-COMPOSITION; HYPOGONADOTROPIC HYPOGONADISM; OLDER MEN; ADIPOSE-TISSUE; DOUBLE-BLIND;
D O I
10.1111/dom.14206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of testosterone in improving sexual symptoms in men with hypogonadism is well known. However, recent studies indicate that testosterone plays an important role in several metabolic functions in males. Multiple PubMed searches were conducted with the use of the terms testosterone, insulin sensitivity, obesity, type 2 diabetes, anaemia, bone density, osteoporosis, fat mass, lean mass and body composition. This narrative review is focused on detailing the mechanisms that underlie the metabolic aspects of testosterone therapy in humans. Testosterone enhances insulin sensitivity in obese men with hypogonadism by decreasing fat mass, increasing lean mass, decreasing free fatty acids and suppressing inflammation. At a cellular level, testosterone increases the expression of insulin receptor beta subunit, insulin receptor substrate-1, protein kinase B and glucose transporter type 4 in adipose tissue and adenosine 5 '-monophosphate-activated protein kinase expression and activity in skeletal muscle. Observational studies show that long-term therapy with testosterone prevents progression from prediabetes to diabetes and improves HbA1c. Testosterone increases skeletal muscle satellite cell activator, fibroblast growth factor-2 and decreases expression of the muscle growth suppressors, myostatin and myogenic regulatory factor 4. Testosterone increases haematocrit by suppressing hepcidin and increasing expression of ferroportin along with that of transferrin receptor and plasma transferrin concentrations. Testosterone also increases serum osteocalcin concentrations, which may account for its anabolic actions on bone. In conclusion, testosterone exerts a series of potent metabolic effects, which include insulin sensitization, maintenance and growth of the skeletal muscle, suppression of adipose tissue growth and maintenance of erythropoiesis and haematocrit.
引用
收藏
页码:18 / 28
页数:11
相关论文
共 100 条
[1]   Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men [J].
Allan, C. A. ;
Strauss, B. J. G. ;
Burger, H. G. ;
Forbes, E. A. ;
McLachlan, R. I. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (01) :139-146
[2]   Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone [J].
Amory, JK ;
Watts, NB ;
Easley, KA ;
Sutton, PR ;
Anawalt, BD ;
Matsumoto, AM ;
Bremner, WJ ;
Tenover, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :503-510
[3]   Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis [J].
Bachman, Eric ;
Feng, Rui ;
Travison, Thomas ;
Li, Michelle ;
Olbina, Gordana ;
Ostland, Vaughn ;
Ulloor, Jagadish ;
Zhang, Anqi ;
Basaria, Shehzad ;
Ganz, Tomas ;
Westerman, Mark ;
Bhasin, Shalender .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (10) :4743-4747
[4]   Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer [J].
Banez, Lionel L. ;
Hamilton, Robert J. ;
Partin, Alan W. ;
Vollmer, Robin T. ;
Sun, Leon ;
Rodriguez, Carmen ;
Wang, Yiting ;
Terris, Martha K. ;
Aronson, William J. ;
Presti, Joseph C., Jr. ;
Kane, Christopher J. ;
Amling, Christopher L. ;
Moul, Judd W. ;
Freedland, Stephen J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (19) :2275-2280
[5]   Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels A Randomized Clinical Trial [J].
Basaria, Shehzad ;
Harman, Mitchell ;
Travison, Thomas G. ;
Hodis, Howard ;
Tsitouras, Panayiotis ;
Budoff, Matthew ;
Pencina, Karol M. ;
Vita, Joseph ;
Dzekov, Connie ;
Mazer, Norman A. ;
Coviello, Andrea D. ;
Knapp, Philip E. ;
Hally, Kathleen ;
Pinjic, Emma ;
Yan, Mingzhu ;
Storer, ThomasW. ;
Bhasin, Shalender .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (06) :570-581
[6]   Risk Factors Associated With Cardiovascular Events During Testosterone Administration in Older Men With Mobility Limitation [J].
Basaria, Shehzad ;
Davda, Maithili N. ;
Travison, Thomas G. ;
Ulloor, Jagadish ;
Singh, Ravinder ;
Bhasin, Shalender .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2013, 68 (02) :153-160
[7]   Adverse Events Associated with Testosterone Administration [J].
Basaria, Shehzad ;
Coviello, Andrea D. ;
Travison, Thomas G. ;
Storer, Thomas W. ;
Farwell, Wildon R. ;
Jette, Alan M. ;
Eder, Richard ;
Tennstedt, Sharon ;
Ulloor, Jagadish ;
Zhang, Anqi ;
Choong, Karen ;
Lakshman, Kishore M. ;
Mazer, Norman A. ;
Miciek, Renee ;
Krasnoff, Joanne ;
Elmi, Ayan ;
Knapp, Philip E. ;
Brooks, Brad ;
Appleman, Erica ;
Aggarwal, Sheetal ;
Bhasin, Geeta ;
Hede-Brierley, Leif ;
Bhatia, Ashmeet ;
Collins, Lauren ;
LeBrasseur, Nathan ;
Fiore, Louis D. ;
Bhasin, Shalender .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02) :109-122
[8]   Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men [J].
Basu, Rita ;
Dalla Man, Chiara ;
Campioni, Marco ;
Basu, Ananda ;
Nair, K. Sreekumaran ;
Jensen, Michael D. ;
Khosla, Sundeep ;
Klee, George ;
Toffolo, Gianna ;
Cobelli, Claudio ;
Rizza, Robert A. .
DIABETES CARE, 2007, 30 (08) :1972-1978
[9]  
BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
[10]   Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline [J].
Bhasin, Shalender ;
Brito, Juan P. ;
Cunningham, Glenn R. ;
Hayes, Frances J. ;
Hodis, Howard N. ;
Matsumoto, Alvin M. ;
Snyder, Peter J. ;
Swerdloff, Ronald S. ;
Wu, Frederick C. ;
Yialamas, Maria A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (05) :1715-1744